Accuracy Evaluation of Circular RNA in Diagnosing Lung Cancer in a Chinese Population

Table 3

Summary results of the subgroup analysis for circRNAs in diagnosing lung cancer.

	Number of studies	Sensitivity (95% CI)	Specificity (95% CI)	PLR (95% CI)	NLR (95% CI)	DOR (95% CI)	AUC
Sample size
Blood	4	0.72 (0.66–0.78)	0.78 (0.66–0.87)	3.30 (2.12–5.15)	0.35 (0.29–0.43)	9.32 (5.35–16.23)	0.78
Tissue	6	0.80 (0.75–0.84)	0.75 (0.66–0.82)	3.16 (2.22–4.49)	0.27 (0.20–0.36)	11.67 (6.36–21.39)	0.84
Lung cancer
Non-small-cell lung cancer	6	0.78 (0.73–0.83)	0.70 (0.66–0.79)	2.87 (2.22–3.72)	0.30 (0.23–0.38)	9.66 (6.00–15.55)	0.82
Lung adenocarcinoma	4	0.75 (0.69–0.79)	0.81 (0.68–0.90)	3.93 (2.20–7.03)	0.31 (0.25–0.40)	12.54 (5.96–26.39)	0.76
Reference gene
GAPDH	9	0.76 (0.72–0.79)	0.75 (0.68–0.81)	3.00 (2.31–3.90)	0.33 (0.28–0.38)	9.41 (6.66–13.31)	0.77
circRNA expression upregulation	8	0.76 (0.72–0.80)	0.77 (0.69–0.84)	3.38 (2.39–4.77)	0.31 (0.25–0.38)	10.96 (6.57–18.29)	0.79

Note: PLR: positive likelihood ratio; NLR: negative likelihood ratio; AUC: area under the receiver operating characteristic curve.